Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
Open access · hybridAbstract readClinical Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 231 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
231citing papers in PubMed, 4 pooled it
30.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
231 citing papers in PubMed, 4 syntheses or guidelines pooled it, 326 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.Journal for immunotherapy of cancer · 2026Guideline
- American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults.Blood advances · 2026Guideline
- CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis.Bone marrow transplantation · 2026Pooled it
- Global Panoramic analysis of clinical research in cell therapy: clinical trial landscape, marketed products, and regulatory trends.Frontiers in pharmacology · 2026Pooled it
- First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL.EBioMedicine · 2025Trial
- Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation.Blood cancer journal · 2025Trial
- JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- First-year results of the International Leukemia/ Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.Haematologica · 2026Article
- Quality and Safety Intervention: Improving Care of Patients Undergoing B Cell-Targeted Therapies.The journal of allergy and clinical immunology. In practice · 2026Article
- Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy.Bone marrow transplantation · 2026Article
- Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients.Cancer chemotherapy and pharmacology · 2026Article
- Review
- CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.Blood advances · 2026Article
- Article
- Incorporating Immunotherapies into the Evolving Standard of Care for Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.Paediatric drugs · 2026Review
- Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost-effectiveness analysis.British journal of haematology · 2026Article
- Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.Haematologica · 2026Article
- A review of genetic modification for ex vivo cellular therapies.Transfusion · 2026Article
- Article
171 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
26 authors at 20 institutions in 13 countries.
Theodore W LaetschDivision of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0002-8497-3138
Shannon L MaudeDivision of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0003-2210-8736
Susana RivesDepartment of Pediatric Hematology-Oncology and Institut de Recerca, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.ORCID 0000-0002-5658-1831
Hidefumi HiramatsuDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Henrique BittencourtDepartment of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, Canada.ORCID 0000-0002-5507-8310
Peter BaderDivision of Stem Cell Transplantation and Immunology, Hospital for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany.ORCID 0000-0003-4554-0265
André BaruchelUniversity Hospital Robert Debré (APHP) and Université de Paris, Paris, France.ORCID 0000-0003-0120-6089
Michael BoyerDepartment of Pediatrics and Internal Medicine, University of Utah, Salt Lake City, UT.
Barbara De MoerlooseDepartment of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-2449-539X
Muna QayedAflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA.ORCID 0000-0001-7689-343X
Jochen BuechnerDepartment of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-5848-4501
Michael A PulsipherDivision of Hematology, Oncology, Blood and Marrow Transplant, Children's Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, CA.ORCID 0000-0003-3030-8420
Gary Douglas MyersChildren's Mercy Hospital and Clinics, Kansas City, MO.
Heather E StefanskiNational Bone Marrow Donor Program, Be the Match, Division of Pediatric Blood and Marrow Transplant, University of Minnesota, Minneapolis, MN.
Paul L MartinPediatric Transplant and Cellular Therapy, Duke University Medical Center, Durham, NC.
Eneida NemecekOregon Health and Science University, Portland, OR.
Christina PetersStem Cell Transplantation Unit, St Anna Children's Hospital, Vienna, Austria.ORCID 0000-0003-0369-8515
Gregory YanikDepartment of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI.
Seong Lin KhawChildren's Cancer Centre, Royal Children's Hospital and Murdoch Children's Research Institute, Parkville, Victoria, Australia.ORCID 0000-0002-9084-8974
Kara L DavisDivision of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0002-7182-2592
Joerg KruegerDivision of Haematology/Oncology/Bone Marrow Transplantation, Hospital for Sick Children, Toronto, Canada.
Adriana BalduzziClinica Pediatrica Università degli Studi di Milano Bicocca, Monza, Italy.ORCID 0000-0002-5879-0610
Nicolas BoisselSaint-Louis Hospital (APHP) and Université de Paris Diderot, Paris, France.
Ranjan TiwariNovartis Healthcare Pvt Ltd, Hyderabad, India.
Darragh O'DonovanNovartis Pharmaceuticals Corporation, Dublin, Ireland.
Stephan A GruppDivision of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0001-8030-7595
Children's Hospital of Philadelphia · USCentre Hospitalier Universitaire Sainte-Justine · CAChildren's Mercy Hospital · USDélégation Paris 7 · FRDuke Medical Center · USEmory University · USGhent University Hospital · BEGoethe University Frankfurt · DEHospital for Sick Children · CAHospital Sant Joan de Déu Barcelona · ESIntermountain Healthcare · USKyoto University · JPNovartis (India) · INNovartis (Ireland) · IEOregon Health & Science University · USOslo University Hospital · NORoyal Children's Hospital · AUStanford University · USSt Anna Children's Hospital · ATUniversité Paris Cité · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Precursor Cell Lymphoblastic Leukemia-LymphomaQuality of LifeChildChronic DiseaseHumansReceptors, Antigen, T-CellRecurrenceYoung AdultReceptors, Antigen, T-Celltisagenlecleucel
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.